NEW YORK, February 25, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting CombiMatrix Corporation (NASDAQ: CBMX), Cepheid (NASDAQ: CPHD), PerkinElmer, Inc. (NYSE: PKI), Life Technologies Corp. (NASDAQ: LIFE) and Laboratory Corp. of America Holdings (NYSE: LH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
CombiMatrix Corporation Research Report
Shares for molecular diagnostics company CombiMatrix surged by 136 percent on the anticipation that it will report impressive fourth quarter results on February 27, 2013. One of the reasons to be excited for the company's report is its recent statement regarding significant growth in its prenatal testing segment. A preliminary growth rate of 172 percent was recorded for the quarter, as well as a preliminary growth rate of 171 percent for the full year. This growth was driven by the company's shift in focus to prenatal molecular diagnostics markets, where chromosomal microarray analysis (CMA) is quickly becoming a standard of care. With solid growth in the company's prenatal test volumes, this anticipation reflected by the company's rise in share price is well merited. The Full Research Report on CombiMatrix Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/4e57_CBMX]
Cepheid Research Report
Cepheid is collaborating with Knight Cancer Institute at Oregon Health & Science University (OHSU) to come up with a menu of advanced molecular diagnostics to be performed on the GeneXpert system. Together, they aim to develop clinical oncology tests, mainly for breast and prostate cancer, the two most common cancers in the US. Many believe that Cepheid's expansion to the oncology arena will drive the company's growth, given its fast growing market. The company also plans to triple its production capacity in 2013. Cepheid now has a broad and expanding menu of tests that run on its GeneXpert systems, including infectious disease, healthcare associated infections (HAI), women's health, genetics and oncology. The Full Research Report on Cepheid - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/cd20_CPHD]
PerkinElmer, Inc. Research Report
PerkinElmer recently announced revenue growth of 6 percent in the fourth quarter of 2012. PerkinElmer CEO Robert Friel comments that he is pleased with the company's strong finish, capping a solid year of revenue growth and adjusted operating margin expansion. As an established market leader in the genetic screening segment, analysts expect the company to continue its strong performance and many commend the company's increased productivity and improved product mix. In the coming year, Friel comments that the company expects to continue making balanced growth and productivity investments, fostering growth and profitability for shareholders while addressing critical health and environment needs. With a competitive pipeline and an innovative staff, many are optimistic about PerkinElmer's prospects. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/f1d2_PKI]
Life Technologies Corp. Research Report
Life Technologies recently announced the purchase of six Ion Torrent sequencers for its new Center for Personalized Medicine (CPM) at Roswell Park Cancer Institute (RPCI). Life Technologies President and COO Mark Stevenson notes that over 1000 organizations have adopted Ion Torrent technology in the past couple of years, giving the company more than 60 percent of the desktop sequencer market. These products will give researchers a simple workflow from discovery to validation. Life Technologies' recent purchase further strengthens its position in the Ion Torrent technology market, and analysts note that this is likely to drive the company forward, given the huge demand for Ion Torrent technology. The company's double-digit growth is also encouraging, along with its solid margins and solid cash flow. The Full Research Report on Life Technologies Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/cd9d_LIFE]
Laboratory Corp. of America Holdings Research Report
LabCorp recently announced that it is investing $2 million in SynapDx, an early stage laboratory services company, to further its development of an autism spectrum disorder test. This investment demonstrates LabCorp's commitment to the development of new and better approaches to ASD diagnosis. Recently, Laboratory Corp also reported net earnings of $120.2 million or $1.26 per share in the fourth quarter of 2012. It also announced a new share buyback program of 1 billion. In the coming year, the company expects higher capital expenditure to increase the volume of tests, boost IT capabilities, improve efficiency, further R&D investments and implement alternative delivery models. LabCorp Chief Executive David King says he expects that the health changes and the MedicAid expansion will ultimately benefit the company by increasing testing volume, and he expects revenue to rise 2 to 3 percent in 2013. The Full Research Report on Laboratory Corp. of America Holdings - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/96dc_LH]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers